Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
Amlitelimab
Placebo
+2 more
Locations
57
United States
Clinical Research Center of Alabama - Homewood- Site Number : 8401101
Birmingham, Alabama, United States
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona, United States
Orange County Clinical Trials- Site Number : 8401271
Anaheim, California, United States
First OC Dermatology- Site Number : 8401025
Fountain Valley, California, United States
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California, United States
Valley Research- Site Number : 8401097
Fresno, California, United States
Start Date
October 6, 2023
Primary Completion Date
October 1, 2025
Completion Date
January 16, 2026
Last Updated
April 13, 2026
NCT05769777
NCT06192563
NCT03687359
NCT03992417
NCT05983068
NCT05235724
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions